FMS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

FM

Mkt Cap

$11.80B

Volume

546.30K

Next Earnings

November 3rd

Loading chart

FM

FMSFresenius Medical Care AG

FMS

Pay with—

Available Balance0.00

FM

Mkt Cap

$11.78B

Volume

546.30K

Next Earnings

November 3rd

Chart Financials Earnings News About Dividends Insider Filings

Reasons to Retain Fresenius Medical Stock in Your Portfolio for NowFresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and showing promise with 5008X dialysis system adoption and value-based care expansion. However, the company faces significant headwinds including U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation concerns. The company maintains a Zacks Rank #3 (Hold) rating with consensus expectations for 2.7% revenue growth but 5.4% earnings decline in 2026.Zacks Investment Research · Oct 7, 2026

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.Zacks Investment Research · Sep 3, 2026

Reasons to Retain Fresenius Medical Stock in Your Portfolio for NowFresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and expanding high-volume HDF and 5008X dialysis systems. However, the company faces significant challenges including persistent U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation-related cost risks. The company maintains a Zacks Rank #3 (Hold) with consensus 2026 earnings expected to decline 7% year-over-year.Zacks Investment Research · Sep 3, 2026

New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA CliffA new analysis by Spherix Global Insights reveals that access barriers, not efficacy issues, are limiting Xphozah (tenapanor) uptake in the dialysis hyperphosphatemia market. Nephrologists report they would nearly triple Xphozah use without reimbursement and coverage obstacles. However, the drug faces persistence challenges with gastrointestinal tolerability causing discontinuation rates to double to 8%. The findings also show physicians significantly overestimate phosphorus control and combination therapy use among patients. As the TDAPA reimbursement program expires at the end of 2026, phosphate-lowering therapies will face a flattened competitive landscape.GlobeNewswire Inc. · Jul 29, 2026

Urology Devices Market Size to Reach USD 80.0 Billion by 2035 | SNS InsiderThe global urology devices market is valued at USD 39.23 billion in 2025 and is projected to reach USD 80.0 billion by 2035, growing at a CAGR of 7.35%. Growth is driven by rising demand for robotic-assisted surgery, kidney disease treatment, and minimally invasive procedures. North America leads the market while Asia Pacific records the fastest growth.GlobeNewswire Inc. · Jul 20, 2026

U.S. Arteriovenous Fistula Devices Market Trends Analysis Report 2025-2033: Lucrative Opportunities Stem from Rising ESRD Cases, Driving Demand for AVF SolutionsThe U.S. arteriovenous fistula devices market is projected to grow from $112 million in 2025 to $120 million by 2033, driven by rising end-stage renal disease cases and increasing demand for advanced vascular access solutions.GlobeNewswire Inc. · Nov 19, 2025

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook ConfidenceQuest Diagnostics reported strong Q1 2025 results, with revenue and earnings beating estimates. The company reaffirmed its full-year guidance and announced strategic acquisitions and partnerships, fueling confidence in its outlook.Benzinga · Apr 22, 2025

Wearable Artificial Organs Global Market Research 2023-2024 & Forecasts to 2034: Government Funding and Initiatives, & Patient Preference for Non-Invasive Solutions Boost GrowthThe global wearable artificial organs market is expected to grow significantly from $11.17 billion in 2024 to $64.19 billion by 2035, driven by government initiatives, technological advancements, and patient preference for non-invasive solutions. North America and Asia Pacific are expected to be the key growth regions.GlobeNewswire Inc. · Jan 23, 2025

China Infusion Systems (Pumps & Pump Disposables) Market Outlook to 2033: Key Companies in China, Pipeline Products, Financial Deals Landscape, Recent Developments & MoreThe report provides a comprehensive analysis of the China infusion systems market, including infusion pumps and infusion pump disposables, with data from 2018 to 2033. It covers key market information, company profiles, pipeline products, and recent developments.GlobeNewswire Inc. · Jan 20, 2025

United States Compounding Pharmacy Market Industry Outlook 2024-2029: Growing Demand for Compounded Bioidentical Menopausal Hormone Therapy (BMHT) Among Women Drives Market GrowthThe U.S. compounding pharmacies market is expected to grow at a CAGR of 4.06% from 2023 to 2029, driven by the growing demand for compounded bioidentical menopausal hormone therapy among women and the increasing adoption of advanced technologies in the industry.GlobeNewswire Inc. · Dec 23, 2024

to start trading

FM

FMSFresenius Medical Care AG

FMS

Pay with—

Available Balance0.00

Your PositionYou don't own any FMS yet.

Related Tickers

Earnings

Dividends

Last · May 22Annual

Amount$0.87

Yield3.93%

Annual$0.87